中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2014年
14期
925-929
,共5页
梁泳荣%柯阳%钟鉴宏%郭哲%姜经航%向邦德
樑泳榮%柯暘%鐘鑒宏%郭哲%薑經航%嚮邦德
량영영%가양%종감굉%곽철%강경항%향방덕
肝细胞癌%总生存率%倾向性评分匹配法%无瘤生存率%胸腺肽α1
肝細胞癌%總生存率%傾嚮性評分匹配法%無瘤生存率%胸腺肽α1
간세포암%총생존솔%경향성평분필배법%무류생존솔%흉선태α1
hepatocellular carcinoma%overall survival rate%propensity score matching%recurrence-free survival rate%thymosin alpha 1
目的：探讨胸腺肽α1（Thymosin alpha 1，Tα1）对肝细胞癌（hepatocellular carcinoma，HCC）患者根治性手术预后的影响。方法：回顾性分析本院2007年1月至2012年12月558例HCC根治性手术后患者，分为Tα1治疗组146例和空白对照组412例，经倾向性评分匹配后，比较两组术后肝功能恢复情况、无瘤生存率和总生存率。结果：两组患者共106对匹配成功，中位随访时间为22个月，治疗组较对照组术后TBIL、ALB、ALT、PT等肝功能指标明显改善（P<0.05）。治疗组和对照组术后1、2、3年无瘤生存率分别为79.7%、70.8%、67.3%和69.9%、61.5%、51.6%（P=0.019）；总生存率分别为87.2%、82.0%、68.4%和78.2%、64.2%、
目的：探討胸腺肽α1（Thymosin alpha 1，Tα1）對肝細胞癌（hepatocellular carcinoma，HCC）患者根治性手術預後的影響。方法：迴顧性分析本院2007年1月至2012年12月558例HCC根治性手術後患者，分為Tα1治療組146例和空白對照組412例，經傾嚮性評分匹配後，比較兩組術後肝功能恢複情況、無瘤生存率和總生存率。結果：兩組患者共106對匹配成功，中位隨訪時間為22箇月，治療組較對照組術後TBIL、ALB、ALT、PT等肝功能指標明顯改善（P<0.05）。治療組和對照組術後1、2、3年無瘤生存率分彆為79.7%、70.8%、67.3%和69.9%、61.5%、51.6%（P=0.019）；總生存率分彆為87.2%、82.0%、68.4%和78.2%、64.2%、
목적：탐토흉선태α1（Thymosin alpha 1，Tα1）대간세포암（hepatocellular carcinoma，HCC）환자근치성수술예후적영향。방법：회고성분석본원2007년1월지2012년12월558례HCC근치성수술후환자，분위Tα1치료조146례화공백대조조412례，경경향성평분필배후，비교량조술후간공능회복정황、무류생존솔화총생존솔。결과：량조환자공106대필배성공，중위수방시간위22개월，치료조교대조조술후TBIL、ALB、ALT、PT등간공능지표명현개선（P<0.05）。치료조화대조조술후1、2、3년무류생존솔분별위79.7%、70.8%、67.3%화69.9%、61.5%、51.6%（P=0.019）；총생존솔분별위87.2%、82.0%、68.4%화78.2%、64.2%、
Objective: The effect of thymosin alpha 1 (Tα1) on patients with hepatocellular carcinoma (HCC) after radical hepatectomy was assessed. Methods: A total of 558 HCC patients treated by radical hepatectomy were retrospectively collected. Patients in the treatment group (n=146) received postoperative Tα1 therapy, whereas patients in the control group (n=412) did not. Propensity scale matching was conducted to improve the balance between the two groups. Changes in liver function, recurrence-free survival rates, and overall survival rates were compared between the two groups. Results: Postoperative liver function (i.e., TBIL, ALB, ALT, and PT) in the treatment group was significantly better than that in the control group (P<0.05). The one-, two-, and three-year recurrence-free survival rates and overall survival rates in the treatment group were significantly higher than those in the control group (P=0.019 and P=0.011, respectively). Conclusion:Postoperative Tα1 therapy can improve postoperative liver function, thus significantly prolonging recurrence-free survival and overall survival.
